Cargando…

A novel serum microRNA signature to screen esophageal squamous cell carcinoma

Circulating microRNAs (miRNAs) have been used as promising diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC). We performed miRNA expression profiling using quantitative reverse transcription polymerase chain reaction (qRT‐PCR) based Exiqon panels from three ESCC pools and one norma...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zebo, Zhang, Lan, Zhu, Danxia, Shan, Xia, Zhou, Xin, Qi, Lian‐wen, Wu, Lirong, Zhu, Jun, Cheng, Wenfang, Zhang, Huo, Chen, Yan, Zhu, Wei, Wang, Tongshan, Liu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269712/
https://www.ncbi.nlm.nih.gov/pubmed/28035762
http://dx.doi.org/10.1002/cam4.973
_version_ 1782501046691561472
author Huang, Zebo
Zhang, Lan
Zhu, Danxia
Shan, Xia
Zhou, Xin
Qi, Lian‐wen
Wu, Lirong
Zhu, Jun
Cheng, Wenfang
Zhang, Huo
Chen, Yan
Zhu, Wei
Wang, Tongshan
Liu, Ping
author_facet Huang, Zebo
Zhang, Lan
Zhu, Danxia
Shan, Xia
Zhou, Xin
Qi, Lian‐wen
Wu, Lirong
Zhu, Jun
Cheng, Wenfang
Zhang, Huo
Chen, Yan
Zhu, Wei
Wang, Tongshan
Liu, Ping
author_sort Huang, Zebo
collection PubMed
description Circulating microRNAs (miRNAs) have been used as promising diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC). We performed miRNA expression profiling using quantitative reverse transcription polymerase chain reaction (qRT‐PCR) based Exiqon panels from three ESCC pools and one normal control (NC) pool samples. Using qRT‐PCR, identified serum miRNAs were further confirmed in training (32 ESCC vs. 32 NCs) and testing stages (108 ESCC vs. 96 NCs). Consequently, five serum miRNAs (miR‐20b‐5p, miR‐28‐3p, miR‐192‐5p, miR‐223‐3p, and miR‐296‐5p) were significantly overexpressed in ESCC compared with NCs. The diagnostic value of the 5‐miRNA signature was validated by an external cohort (60 ESCC vs. 60 NCs). The areas under the receiver operating characteristic curve (ROC) of the 5‐miRNA signature were 0.753, 0.763, and 0.966 for the training, testing, and the external validation stages, respectively. The expression levels of the miRNAs were also determined in tissues, arterial serum, and exosomes. MiR‐20b‐5p, miR‐28‐3p, and miR‐192‐5p were significantly upregulated in ESCC tissues, while miR‐296‐5p was overexpressed in ESCC serum exosomes. In conclusion, we identified a 5‐miRNA signature in serum for the detection of ESCC.
format Online
Article
Text
id pubmed-5269712
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52697122017-02-01 A novel serum microRNA signature to screen esophageal squamous cell carcinoma Huang, Zebo Zhang, Lan Zhu, Danxia Shan, Xia Zhou, Xin Qi, Lian‐wen Wu, Lirong Zhu, Jun Cheng, Wenfang Zhang, Huo Chen, Yan Zhu, Wei Wang, Tongshan Liu, Ping Cancer Med Clinical Cancer Research Circulating microRNAs (miRNAs) have been used as promising diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC). We performed miRNA expression profiling using quantitative reverse transcription polymerase chain reaction (qRT‐PCR) based Exiqon panels from three ESCC pools and one normal control (NC) pool samples. Using qRT‐PCR, identified serum miRNAs were further confirmed in training (32 ESCC vs. 32 NCs) and testing stages (108 ESCC vs. 96 NCs). Consequently, five serum miRNAs (miR‐20b‐5p, miR‐28‐3p, miR‐192‐5p, miR‐223‐3p, and miR‐296‐5p) were significantly overexpressed in ESCC compared with NCs. The diagnostic value of the 5‐miRNA signature was validated by an external cohort (60 ESCC vs. 60 NCs). The areas under the receiver operating characteristic curve (ROC) of the 5‐miRNA signature were 0.753, 0.763, and 0.966 for the training, testing, and the external validation stages, respectively. The expression levels of the miRNAs were also determined in tissues, arterial serum, and exosomes. MiR‐20b‐5p, miR‐28‐3p, and miR‐192‐5p were significantly upregulated in ESCC tissues, while miR‐296‐5p was overexpressed in ESCC serum exosomes. In conclusion, we identified a 5‐miRNA signature in serum for the detection of ESCC. John Wiley and Sons Inc. 2016-12-30 /pmc/articles/PMC5269712/ /pubmed/28035762 http://dx.doi.org/10.1002/cam4.973 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Huang, Zebo
Zhang, Lan
Zhu, Danxia
Shan, Xia
Zhou, Xin
Qi, Lian‐wen
Wu, Lirong
Zhu, Jun
Cheng, Wenfang
Zhang, Huo
Chen, Yan
Zhu, Wei
Wang, Tongshan
Liu, Ping
A novel serum microRNA signature to screen esophageal squamous cell carcinoma
title A novel serum microRNA signature to screen esophageal squamous cell carcinoma
title_full A novel serum microRNA signature to screen esophageal squamous cell carcinoma
title_fullStr A novel serum microRNA signature to screen esophageal squamous cell carcinoma
title_full_unstemmed A novel serum microRNA signature to screen esophageal squamous cell carcinoma
title_short A novel serum microRNA signature to screen esophageal squamous cell carcinoma
title_sort novel serum microrna signature to screen esophageal squamous cell carcinoma
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269712/
https://www.ncbi.nlm.nih.gov/pubmed/28035762
http://dx.doi.org/10.1002/cam4.973
work_keys_str_mv AT huangzebo anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhanglan anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhudanxia anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT shanxia anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhouxin anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT qilianwen anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT wulirong anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhujun anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT chengwenfang anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhanghuo anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT chenyan anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhuwei anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT wangtongshan anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT liuping anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT huangzebo novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhanglan novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhudanxia novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT shanxia novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhouxin novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT qilianwen novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT wulirong novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhujun novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT chengwenfang novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhanghuo novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT chenyan novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT zhuwei novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT wangtongshan novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma
AT liuping novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma